Two things can be true.
(00:14) Bill Barker and Ricky Mulvey discuss:
- Legislation to ban DeepSeek on US government devices.
- Hershey’s quarter, and what it reveals about American eating habits.
- Eli Lilly’s blockbuster weight-loss drugs, and questions about its valuation.
Then, (18:26) Ricky continues his conversation with writer Jordan Harper about th ... Show More
Nov 2024
Industries React to Trump Tariffs & Drake-Kendrick Beef Goes to Court
Episode 462: Neal and Toby examine what Trump’s broad tariffs on China, Mexico, and Canada could mean for everyday goods for millions of Americans. Then, the Biden administration is proposing to expand medicare and medicaid to foot the bill for popular weight-loss drugs like Ozem ... Show More
31m 10s
Feb 2024
The obesity drug craze is entering its next phase
Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ... Show More
22m 46s
Aug 2025
Deep Dive: Novo Nordisk & Eli Lilly Stumble Into Next Phase of Ozempic Era
Two pharma giants, Eli Lilly and Novo Nordisk, are in a high-stakes race for leadership in the $150 billion GLP-1 obesity drug market. We examine Lilly’s latest earnings, the mixed results from its oral pill orforglipron, and Novo’s push with higher-dose oral semaglutide. We also ... Show More
11m 3s
Oct 2024
Weight Loss Drug Ads: Good or Bad?
Companies are spending big bucks advertising weight-loss drugs like Ozempic and Rybelsus. This week, we’re dropping an episode of Brian Goldman’s White Coat, Black Art podcast into our feed.We thought you might find the topic interesting. In Canada, "reminder ads" can only give t ... Show More
27m 8s